Live Breaking News & Updates on Fiscal Fourth Quarter Ended March|Page 1

Stay updated with breaking news from Fiscal fourth quarter ended march. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

29.05.2024 - Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year . ....

Chau Cheng , Exchange Commission , Neurology Clinical Development Updates , Due To Roivant Sciences Ltd , General Clinical Development Updates , Endocrinology Clinical Development Updates , Immunovant Inc , Clinical Development Updates , Thyroid Eye Disease , Insulin Growth Factor , Fiscal Fourth Quarter Ended March , Fiscal Year Ended March , Private Securities Litigation Reform Act , Annual Report , Roivant Sciences ,

Bowflex Parent, Nautilus, Inc. Reports Fourth Quarter and Full Year Fiscal 2023 Results

Direct Segment Net Sales of $139 Million Up 16% versus Pre-pandemic Fiscal 2020

Reaches 508K JRNY® Members During Q4 Fiscal 2023, Up 56% versus Q4 Fiscal 2022

Adjusted EBITDA Loss Reduced by. | May 23, 2023 ....

United States , British Columbia , Jim Barr , Aina Konold , Nautilus Inc , Exchange Commission , Bowflex Parent , North Star , Chief Executive , Fourth Quarter Ended March , Fiscal Fourth Quarter Ended March , Year Ended March , Fiscal Year Ended March , Excluding Nautilus , Emotion Tracking , Segment Results , Year Fiscal , Nautilus Brand , Chief Executive Officer , Chief Financial , North America , Private Securities Litigation Reform Act , Annual Report , Home Gyms , Months Ended March , Illegal Settlement ,

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

22.05.2023 - Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectivelyPhase 1 clinical trial in healthy subjects initiated in New ZealandPhase 2 proof-of-concept clinical trial of . ....

New Zealand , Chau Cheng , Clinical Development Updates , Exchange Commission , Immunovant Inc , Due To Roivant Sciences Ltd , Drug Administration , Fiscal Fourth Quarter Ended March , Fiscal Year Ended March , Private Securities Litigation Reform Act , Annual Report , Roivant Sciences ,

Kyndryl Reports Fourth Quarter and Full-Year 2023 Results

Revenues for the quarter ended March 31, 2023 total $4.3 billion, net loss is $737 million, adjusted EBITDA is $476 million, and adjusted pretax loss is $61 million

Fiscal year 2023 revenues. | May 16, 2023 ....

United Kingdom , New Zealand , United States , Martin Schroeter , David Wyshner , Kyndryl Holdings Inc , Exchange Commission , Company Form , Company Annual Report On Form , Kyndryl Holdings , Kyndryl Chairman , Chief Executive Officer Martin , Kyndryl Consult , Fiscal Fourth Quarter Ended March , Fiscal Year Ended March , Kyndryl Chief Financial Officer David , Advanced Delivery , Conference Call , Private Securities Litigation Reform Act , Annual Report , Months Ended March , Ended March , Strategic Markets , Nc Stock Exchange , Press Release , 023 Kd Us50155q1004 ,